Benefits and Risks to Mother and Infant of Drug Treatment for Postnatal Depression
- 1 January 2002
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 25 (13) , 903-911
- https://doi.org/10.2165/00002018-200225130-00002
Abstract
The postnatal period presents a special problem to healthcare providers treating psychiatric disorders in women. Many new mothers who need antidepressant treatment may wish to breastfeed their...Keywords
This publication has 83 references indexed in Scilit:
- Effects of Early Maternal Depression on Patterns of Infant‐Mother Attachment: A Meta‐analytic InvestigationJournal of Child Psychology and Psychiatry, 2000
- Paroxetine in human milkBritish Journal of Clinical Pharmacology, 1999
- Distribution and excretion of venlafaxine and O‐desmethylvenlafaxine in human milkBritish Journal of Clinical Pharmacology, 1998
- Excretion of citalopram in breast milkBritish Journal of Clinical Pharmacology, 1997
- Group Treatment for Postpartum Depression: A Pilot StudyAustralian & New Zealand Journal of Psychiatry, 1996
- Excretion of Fluoxetine and Its Metabolite, Norfluoxetine, in Human Breast MilkThe Journal of Clinical Pharmacology, 1996
- Clinical Pharmacokinetics of FluoxetineClinical Pharmacokinetics, 1994
- Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum.Journal of Consulting and Clinical Psychology, 1989
- A Prospective Study of Emotional Disorders in Childbearing WomenThe British Journal of Psychiatry, 1984
- Prospective study of postpartum depression: Prevalence, course, and predictive factors.Journal of Abnormal Psychology, 1984